SB 2737 creates the Mississippi Kratom Consumer Protection Act, a regulatory framework for the sale of kratom leaf and kratom products in Mississippi. The bill defines kratom leaf, kratom extract, kratom products, synthesized and semi-synthesized alkaloids, and products considered “attractive to children.” It then sets a series of consumer-protection rules, including a minimum sales age of 21, online age-verification requirements, limits on 7-hydroxymitragynine potency, and a ban on products that resemble candy or child-oriented shapes. It also prohibits kratom products adulterated with synthesized or semi-synthesized kratom constituents and restricts public-access displays unless supervised or otherwise secured.
The bill also imposes manufacturing, packaging, and labeling standards. Kratom products sold in Mississippi would have to comply with federal dietary supplement good manufacturing practices and be produced by FDA-registered processors. Labels would need to include warnings about use by minors, pregnancy and breastfeeding, possible drug interactions, habit-forming potential, FDA disclaimer language, business identification, serving directions, and quantitative amounts of mitragynine and 7-hydroxymitragynine per serving. The bill takes effect July 1, 2025, and includes civil penalties and a three-year sales prohibition for repeated violations. It also preempts local governments from imposing stricter kratom rules than those in the act.
The bill’s impact on state law would be to establish the first statewide Mississippi regulatory scheme specifically for kratom retail sales and product standards, while also creating a new 5% privilege tax on retail kratom sales. It would affect retailers, online marketplaces, processors, distributors, and manufacturers by imposing age checks, product-composition limits, registration expectations, labeling duties, and enforcement penalties. Localities would lose authority to adopt more restrictive kratom regulations, making the state law the controlling standard.
Because there are no committee transcripts or recorded votes provided, the overall sentiment cannot be measured from legislative debate or roll call history. Based on the bill text alone, the measure appears framed as a consumer-protection and product-safety bill rather than a prohibition bill, suggesting a regulatory rather than punitive approach to kratom. The absence of recorded opposition or support in the provided materials leaves the public and legislative sentiment unclear.
The main points of contention likely center on whether kratom should be regulated as a consumer product at all, the appropriateness of a 21-and-over sales limit, the potency cap on 7-hydroxymitragynine, and the ban on synthesized or semi-synthesized alkaloids. Retailers and kratom industry participants may object to the tax, registration, labeling, and preemption provisions, while public health advocates may focus on youth access, product adulteration, and marketing to children. The bill’s preemption clause could also be controversial for local governments that want stricter controls.
SB 2737 would add a new chapter of Mississippi law governing kratom sales, manufacturing, labeling, and enforcement. It would require age verification for online sales, restrict sales to persons under 21, prohibit certain product formulations and child-appealing packaging, require FDA-compliant manufacturing and registration, and mandate detailed warning labels and ingredient disclosures. It would also impose a 5% privilege tax on retail kratom sales, create civil penalties and a sales ban for repeat violations, and preempt local governments from imposing stricter kratom rules.
No committee discussion or vote record is provided, so there is no direct evidence of legislative support or opposition in the available materials. The bill’s structure suggests a consumer-protection approach that may appeal to lawmakers seeking to regulate kratom rather than ban it, but the lack of transcripts and votes makes the actual sentiment indeterminate.
Likely areas of contention include the 21-year-old sales restriction, the online age-verification mandate, the 2% cap on 7-hydroxymitragynine, and the prohibition on synthesized or semi-synthesized kratom compounds. Retailers and kratom businesses may also object to the 5% privilege tax, FDA registration requirement, and labeling obligations, while local governments may resist the preemption clause that blocks stricter municipal regulation. Public health supporters may favor these restrictions as safeguards against youth access, adulteration, and misleading marketing.